The most active peptide that competed with the VEGF binding to its receptor exerted anti-angiogenic activity both in vitro (preventing human endothelial cell proliferation) and in vivo (in the chick embryo chorioallantoic membrane) and reduced tumor growth in mice [110]. The gene discussed is VEGFA; the disease is neoplasm.